Sorrento Therapeutics

Sorrento Therapeutics' mission is to apply cutting-edge science to develop innovative therapies for cancer, pain, and COVID-19. The company has historically grown through an aggressive acquisition strategy, amassing a diverse toolkit of technology platforms including a fully human antibody library, CAR-T, oncolytic viruses, and non-opioid pain delivery. Despite building an extensive pipeline, Sorrento faces severe financial distress, having filed for Chapter 11 bankruptcy in February 2023 to facilitate a strategic restructuring while attempting to advance key clinical assets.

Sorrento's core platforms include the G-MAB™ fully human antibody library for antibody discovery, CAR-T and oncolytic virus (Seprehvec™) platforms for oncology, and the Sofusa® lymphatic drug delivery technology for non-opioid pain management.

Faces entrenched, well-funded competitors in oncology (e.g., AstraZeneca, Johnson & Johnson in BTK/EGFR space) and pain management. Sorrento's financial distress places it at a significant operational disadvantage, making differentiation through novel mechanisms critical but challenging to fund.